reports
Aegon trading update for third quarter 2025
Aegon trading update for third quarter 2025 Schiphol, November 13, 2025 - Please click to access all 3Q 2025 trading update related documents. EUR 340 million operating capital generation (OCG) before holding funding and operating expensesCapital ratios of Aegon’s main units remain strong, above their respective operating levelsCash Capital at Holding at EUR 1.9 billion, reflecting the sale of 12.5 million shares in a.s.r. for EUR 700 million, the payment of the 2024 final dividend and the 2025 interim dividend, and 54% completion of the ongoing EUR 400 million share buyback programOn tr...
Crescent NV: 2 directors
Two Directors at Crescent NV bought/sold 95,490,000 shares at between 0.007EUR and 0.007EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Fagron’s share buy-back program: Weekly update
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025. The total numbe...
Voortgang aandeleninkoopprogramma Fagron
Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 7 november 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 3 november 2025 tot en met 7 november 2025 heeft Fagron 45.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20.4413 per aandeel wat overeenkomt met een totaalbedrag van € 919.856,70. Deze aankopen zijn gedaan als onderdeel van het aandeleninkoopprogramma van maximaal 200.000 Fagron aandelen ter afdekking van Fagron’s verplichtingen uit hoofde van haar langetermijn variabele belonings...
- Jacob Mekhael
- Emira Sagaama
- Hela Zarrouk
- Michael Foundoukidis
- Oliver Metzger
SESGL SES SA FDR (CLASS A)
RNO RENAULT SA
DAI DAIMLER AG
FGA FIGEAC AERO SA
LXS LANXESS AG
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
BAMNB KONINKLIJKE BAM GROEP NV
GN GN STORE NORD A/S
SOLB SOLVAY SA
VOW3 VOLKSWAGEN AG PREF
GLB GLANBIA PLC
FIE FIELMANN AG
LNZ LENZING AG
DEZ DEUTZ AG
CFT COMPAGNIE FINANCIERE TRADITION
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
MELE MELEXIS NV
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
11B 11 BIT STUDIOS S.A.
DIC DIC ASSET AG
WLN WORLDLINE SA
FNTN FREENET AG
GLPG GALAPAGOS NV
ATRY ATRYS HEALTH
INS INSTONE REAL ESTATE GROUP AG
S30 SOLUTIONS 30 SE
FSNT FASHIONETTE AG
STLA STELLANTIS N.V.
ANTIN ANTIN INFRASTRUCTURE PARTNERS
HGEA HGEARS AG
CTPNV CTP NV
FI-N GEORG FISCHER AG
VT5 VT5 ACQUISITION COMPANY AG
SHUR SHURGARD SELF STORAGE LIMITED
AF AIR FRANCE - KLM
- Emira Sagaama
- Hela Zarrouk
- Michael Foundoukidis
- Oliver Metzger
FGA FIGEAC AERO SA
LXS LANXESS AG
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
BAMNB KONINKLIJKE BAM GROEP NV
GN GN STORE NORD A/S
SOLB SOLVAY SA
GLB GLANBIA PLC
FIE FIELMANN AG
LNZ LENZING AG
DEZ DEUTZ AG
CFT COMPAGNIE FINANCIERE TRADITION
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
MELE MELEXIS NV
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
11B 11 BIT STUDIOS S.A.
DIC DIC ASSET AG
WLN WORLDLINE SA
FNTN FREENET AG
GLPG GALAPAGOS NV
ATRY ATRYS HEALTH
INS INSTONE REAL ESTATE GROUP AG
S30 SOLUTIONS 30 SE
FSNT FASHIONETTE AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
HGEA HGEARS AG
FI-N GEORG FISCHER AG
VT5 VT5 ACQUISITION COMPANY AG
SHUR SHURGARD SELF STORAGE LIMITED
AF AIR FRANCE - KLM
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Martial Descoutures
- Jacob Mekhael
Galapagos 9M25 results hold no surprises, new outlook following cell T...
Galapagos reported 9M25 results with a cash position of € 3,050m (YE24: € 3,317.8m) and an updated outlook, where it expects to end FY25 with € 2,975- € 3,025m in cash, and to incur costs of € 250-325m related to the winddown of the cell therapy business. Looking ahead, the company will focus its strategy on building a new pipeline through BD, and more information on BD strategy will be provided during this afternoon's conference call. € 37 TP and ACCUMULATE maintained.
Galapagos Reports Nine Months 2025 Financial Results and Provides Busi...
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET ...
Galapagos rapporteert financiële resultaten over de eerste negen maand...
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 2025 en geeft bedrijfsupdate Strategisch evaluatieproces afgerond met de intentie om de celtherapieactiviteiten af te bouwen, wat de optimale kapitaalallocatie vertegenwoordigt ter ondersteuning van een sterkere en duurzame toekomst voor GalapagosVerdere ontwikkeling van het leiderschapsteam sluit aan bij de strategische richtingRobuuste balans met €3,05 miljard in geldmiddelen en financiële investeringen per 30 september 2025; verwachte kaspositie eind 2025 tussen €2,975 miljard en €3,025 miljardManagement organis...
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
ASH abstracts: Autolus, Galapagos, MaaT
The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
Galapagos to Present New Data from Cell Therapy Program at ASH 2025 Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform, potentially enabling broader access to cell the...
Galapagos zal nieuwe gegevens presenteren over celtherapieprogramma ti...
Galapagos zal nieuwe gegevens presenteren over celtherapieprogramma tijdens ASH 2025 Mondelinge presentatie van GLPG5101-gegevens uit de ATALANTA-1 studie bij patiënten met hoog-risico recidief/refractair mantelcellymfoom Twee abstracts met nieuwe fase 2-gegevens benadrukken het potentieel van CAR-T-celtherapie kandidaat GLPG5101 in recidief/refractaire non-hodgkin lymfoom Resultaten tonen hoge percentages van volledige en duurzame responsen, gecombineerd met lage percentages van ernstige toxiciteiten met GLPG5101, geproduceerd via een innovatief platform met een mediane vein-to-vein tijd...
Aegon announces changes to its Board of Directors
Aegon announces changes to its Board of Directors Schiphol, November 3, 2025 - Aegon announces today that David Herzog, who was appointed as a member of the Board of Directors (BoD) at Aegon’s 2025 Annual General Meeting of shareholders (AGM), will succeed William Connelly as Chairman of the BoD as of November 13, 2025. In line with previous announcements, Mr Connelly will retire as Chairman and member of the BoD on the same date. Aegon also announces today that it will propose to its 2026 AGM to appoint Leni Boeren as a new member of its BoD. Mrs Boeren has extensive experience in both t...
Fagron’s share buy-back program: Weekly update
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 27 October 2025 through 31 October 2025, Fagron purchased 46,000 of its owns shares at an average price of €20.5831 per share corresponding to a total amount of €946,821.80. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025. The total numbe...
Voortgang aandeleninkoopprogramma Fagron
Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 31 oktober 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 27 oktober 2025 tot en met 31 oktober 2025 heeft Fagron 46.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20.5831 per aandeel wat overeenkomt met een totaalbedrag van € 946.821,80. Deze aankopen zijn gedaan als onderdeel van het aandeleninkoopprogramma van maximaal 200.000 Fagron aandelen ter afdekking van Fagron’s verplichtingen uit hoofde van haar langetermijn variabele belonings...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.